Le Lézard
Classified in: Health
Subjects: PDT, FDA, DIS

ENvizion's Personalized Feeding Tube Placement Device Receives FDA 510(k) Clearance

TEL AVIV, Israel, April 2, 2019 /PRNewswire/ -- 

ENvizion Logo (PRNewsfoto/ENvizion Medical)

ENvizion Medical announced that the ENvuetm Electromagnetic Feeding Tube Placement System and ENvizion Feeding Tubes received FDA 510(k) clearance. This new generation of electromagnetic placement technology addresses current technological limitations and meets the growing clinical need for accurate feeding tube placement at bedside.

Globally, over 22 million nasal feeding tubes are placed annually, out of which 6 million are in the USA. The main challenge is to place and position the tube correctly in the GI tract, avoiding the lungs. Current insertion methodologies are limited and it is estimated that 1 million tubes are misplaced annually worldwide. Misplacement of the tube in the lungs can cause significant patient injury, including death, and lead to prolonged hospital stay with extensive additional hospital costs.
This troubling challenge has significantly raised awareness among healthcare providers and patient advocacy groups, leading to the search for new dependable solutions.

ENvizion's unique technology enables accurate enteral placement. Using multiple sensors and an electromagnetic field, the ENvue system creates a personalized roadmap of the patient's anatomy, displaying continuous tube tip position within the body during the insertion procedure. The healthcare professional placing the tube has access to multiple views and warning indicators, which allows visual verification that the tube is proceeding along the correct path, and not entering the lungs.

Results from a clinical trial conducted at leading US hospitals, demonstrated that the ENvue system is safe and effective, with no tube insertions into the pulmonary airways and no occurrence of guidance-related adverse events.

Using the ENvue system has the potential to eliminate the need for additional placement verification methods (x-rays and pH measurements).

ENvizion Medical

ENvizion Medical's is a privately held medical device company, in the field of nasoenteral feeding.
The company's ENvuetm Electromagnetic Feeding Tube Placement System, including nasoenteral feeding tubes, supports the rising clinical need for a safe and accurate feeding tube placement solution, contributing to patient health and improved healthcare. Cleared and indicated for use in the USA, the ENvue system features our proprietary electromagnetic placement technology.

Founded in 2014, ENvizion is located in Tel Aviv, Israel, with US headquarters in Minneapolis, MN.
Connect on LinkedIn: https://www.linkedin.com/company/envizionmedical/ 

Doron Besser, M.D.
CEO ENvizion Medical Ltd.


SOURCE ENvizion Medical

These press releases may also interest you

at 16:05
Rocket Pharmaceuticals, Inc. ("Rocket"), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces the closing of its previously announced underwritten public...

at 16:05
Horizon Therapeutics plc today announced that the Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) of the U.S. Food and Drug Administration (FDA) voted unanimously that the potential benefits of teprotumumab, a fully human monoclonal...

at 16:02
Michael D. Most, MD, FACS, is being recognized by Continental Who's Who as a Pinnacle Lifetime Achiever in the field of Medicine in recognition of his role as a Surgeon. Backed by twelve years of experience, Dr. Most is one of the top head and neck...

at 16:01
K-Bro Linen Inc. (the "Corporation") announced today a dividend of 10.00 cents CDN per common share of the Corporation for the period from December 1 to 31, 2019, to be paid on January 15, 2020 to holders of record of common shares on December 31,...

at 16:00
Attainia today announced that Michael Burns has been named VP, Sales. With more than 1,000 member hospital locations, Attainia is the world's most widely used equipment planning, budgeting, and tracking system software for healthcare equipment. "I am...

at 16:00
The Muscular Dystrophy Association (MDA) today celebrated the decision by the US Food and Drug Administration (FDA) to grant accelerated marketing approval to golodirsen (Vyondys 53) for the treatment of Duchenne muscular dystrophy (DMD) in patients...

News published on 2 april 2019 at 10:15 and distributed by: